Major Haemorrhage during Vitamin K Antagonist Treatment: The Influence of Thyroid Hormone Levels | Zendy

J. Debeij | Zendy; Suzanne C. Cannegieter | Zendy; Bregje van Zaane | Zendy; Anton P. van Zanten | Zendy; Frits R. Rosendaal | Zendy; Victor E. A. Gerdes | Zendy; Pieter H. Reitsma | Zendy; Olaf M. Dekkers | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Major Haemorrhage during Vitamin K Antagonist Treatment: The Influence of Thyroid Hormone Levels

Author(s) -

J. Debeij,

Suzanne C. Cannegieter,

Bregje van Zaane,

Anton P. van Zanten,

Frits R. Rosendaal,

Victor E. A. Gerdes,

Pieter H. Reitsma,

Olaf M. Dekkers

Publication year - 2014

Publication title -

european thyroid journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.23

H-Index - 10

eISSN - 2235-0802

pISSN - 2235-0640

DOI - 10.1159/000357578

Subject(s) - medicine , odds ratio , gastroenterology , vitamin k antagonist , confidence interval , hormone , thrombosis , thyroid , endocrinology , warfarin , atrial fibrillation

Annually, approximately 1-3% of patients treated with vitamin K antagonists (VKA) suffer from major haemorrhage. Since high levels of free thyroxine (fT4) are associated with increased thrombosis risk, the aim was to assess whether low levels of fT4 contribute to major haemorrhage in patients under VKA treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research